Evidence map›Paper›PMID 36279396›Full record

ArticleAging2022

Renoprotective effect of Tanshinone IIA against kidney injury induced by ischemia-reperfusion in obese rats.

He Tai, Xiao-Zheng Cui, Jia He, Zhi-Ming Lan, Shun-Min Li, Ling-Bing Li, Si-Cheng Yao, Xiao-Lin Jiang, Xian-Sheng Meng, Jin-Song Kuang

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Rodent models of AKI and AKI-CKD transition: an update in 2024.American journal of physiology. Renal physiology · 2024
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

He TaiSchool of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China.
Xiao-Zheng CuiCardiovascular Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Jia HePost-Doc Mobile Station, Liaoning University of Traditional Chinese Medicine, Shenyang, China.
Zhi-Ming LanPost-Doc Mobile Station, Liaoning University of Traditional Chinese Medicine, Shenyang, China.
Shun-Min LiNephrology Laboratory, The Fourth of Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine (Shenzhen Traditional Chinese Medicine Hospital), Guangzhou University of Traditional Chinese Medicine, Shenzhen, China.
Ling-Bing LiDepartment of Graduate School, China PLA General Hospital, Beijing, China.
Si-Cheng YaoKey Laboratory of Ministry of Education for Traditional Chinese Medicine Viscera-State Theory and Applications, Liaoning University of Traditional Chinese Medicine, Shenyang, China.
Xiao-Lin JiangNephrology Laboratory, The Fourth of Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine (Shenzhen Traditional Chinese Medicine Hospital), Guangzhou University of Traditional Chinese Medicine, Shenzhen, China.
Xian-Sheng MengSchool of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China.
Jin-Song KuangDepartment of Endocrinology and Metabolism, The Fourth People's Hospital of Shenyang, Shenyang, China.
Liaoning University of Traditional Chinese Medicine · CNGuangzhou University · CNBeijing Tsinghua Chang Gung Hospital · CNChinese PLA General Hospital · CNThe Fourth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveObesity enhances the frequency and severity of acute kidney injury (AKI) induced by renal ischemia-reperfusion (IR). Tanshinone IIA (TIIA) pre-treatment was used to alleviate renal injury induced by renal IR, and whether TIIA can attenuate renal cell apoptosis via modulating mitochondrial function through PI3K/Akt/Bad pathway in obese rats was examined.

methodsMale rates were fed a high-fat diet for 8 weeks to generate obesity, followed by 30 min of kidney ischemia and 24 h reperfusion induced AKI. The male obese rates were given TIIA (5 mg/kg.d, 10 mg/kg.d, and 20 mg/kg.d) for 2 weeks before renal IR.

resultsTIIA alleviated the pathohistological injury and apoptosis induced by IR. In addition, TIIA improved renal function, inflammatory factor, and balance of oxidation and antioxidation in obese rats after renal IR. At the same time, TIIA can inhibit cell apoptosis by improving mitochondrial function through the PI3K/Akt/Bad pathway. Mitochondrial dysfunction was supported by decreasing intracellular ATP, respiration controlling rate (RCR), mitochondrial membrane potential (MMP), and mitochondrial respiratory chain complex enzymes, and by increasing ROS, the opening of mitochondrial permeability transition pore (mPTP), and the mtDNA damage. The injury to mitochondrial dynamic function was assessed by decreasing Drp1, and increasing Mfn1/2; and the injury of mitochondrial biogenesis was assessed by decreasing PGC-1, Nrf1, and TFam.

conclusionsRenal mitochondrial dysfunction occurs along with renal IR and can induce renal cell apoptosis. Obesity can aggravate apoptosis. TIIA can attenuate renal cell apoptosis via modulating mitochondrial function through PI3K/Akt/Bad pathway in obese rats.

Indexed as

Acute Kidney InjuryMyocardial Reperfusion InjuryAbietanesAnimalsApoptosisIschemiaKidneyMaleObesityPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRatsReperfusionAbietanesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akttanshinoneacute kidney injuryapoptosismitochondrial dysfunctionrenal ischemia-reperfusionTanshinone IIA

Identifiers

PMID36279396
PMCPMC9648803
OpenAlexW4306941113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.